Phase 3 Trial Finds Tysabri Lowers Serum Neurofilament Light Levels in SPMS Patients
MAY 7, 2019 BY JOSE MARQUES LOPES, PHD Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain…
Decline in Brain Volume Driven by Gray Matter Atrophy in MS Patients Despite Tysabri Treatment
BY JONATHAN GRINSTEIN This finding points to new markers for MS disease progression, and the need to monitor the effectiveness of treatment…
Stuart Schlossman
Tysabri Seen as Superior to IFN-β in Preventing Relapses, Easing Disability in Small Study
DECEMBER 7, 2018 BY ALBERTO MOLANO Tysabri (natalizumab) was found to be superior to interferon beta (IFN-β) in a small, 12-month…
Stuart Schlossman
Tysabri Seen to Improve Cognition in RRMS Patients Over 2 Years in Retrospective Study
SEPTEMBER 6, 2018 BY MARTA FIGUEIREDO Tysabri (natalizumab) was reported in a small retrospective study to significantly improve cognitive abilities in people…
Stuart Schlossman
Smoking Increases Relapse Rate in RRMS Patients on Tysabri, Study Suggests
August 7, 2018 Smoking increases the relapse rate in patients with relapsing-remitting multiple sclerosis being treated with Tysabri , an…
Stuart Schlossman
Natalizumab May Reduce Disease Progression in Multiple Sclerosis
For patients with secondary progressive multiple sclerosis, natalizumab was not superior to placebo for reducing disability progression, according to results published…
Stuart Schlossman
Tysabri-associated Progressive Multifocal Leukoencephalopathy (PML)
Discussed by Aaron Boster, MD What is PML, what causes it, and the risk factors for infection associated with taking…
Stuart Schlossman
Cognitive functioning following one-year Natalizumab treatment: A non-randomized clinical trial.
Rorsman I, et al. Acta Neurol Scand. 2017. Show full citation Abstract OBJECTIVES: Cognitive impairment is common in multiple sclerosis (MS)…
Stuart Schlossman
Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study.
…
Stuart Schlossman
Natalizumab in Multiple Sclerosis: Long-Term Management
…
Stuart Schlossman
